Recurrence Rates and Risk Factors for Primary Giant Cell Tumors around the Knee: A Multicentre Retrospective Study in China

Hu, Pan; Zhao, Liqun; Zhang, Huilin; Yu, Xiuchun; Wang, Zhen; Ye, Zhaoming; Wu, Sujia; Guo, Sisi; Zhang, Guochuan; Wang, Jinghua; Ning, Xianjia; Hu, Yongcheng; Zhang, Yingze

doi:10.1038/srep36332

Cited by 41 publications

(49 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Table 1 , the summary of recent studies of benign GCT in China (and Japan) feature more males than females diagnosed with GCT and a mean age at diagnosis ranging from 30.5 to 35.7 years [21] , [22] , [23] , [24] . Other studies, including a study with 1,536 patients reported by Niu et al and published in 2015, have reported that benign GCT accounts for 13.7% to 16.7% of bone tumors [9] , [10] , [11] , [12] .…”

Section: Resultsmentioning

confidence: 99%

Epidemiology of benign giant cell tumor of bone in the Chinese population

Liede

Hernandez

Tang³

et al. 2018

Journal of Bone Oncology

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Epidemiology of benign giant cell tumor of bone in the Chinese population

Liede

Hernandez

Tang³

et al. 2018

Journal of Bone Oncology

View full text Add to dashboard Cite

show abstract

“…Cement has been shown to reduce local recurrence in some study, while others hold that its effect was not significant. Hu reported that the recurrent rate of patients treated with bone‐graft filling and bone cement was 40.9% (18 of 44) and 35.4 (45 of 127) with no significant difference between them ( P = 0.516). In our series, the local recurrence of patients filled with cement and bone graft was 42.6% (40 of 94) and 42.9% (18 of 42) respectively and we also did not observe significant difference ( P = 0.981) (Table ).…”

Section: Discussionmentioning

confidence: 99%

“…Giant cell tumors of bone (GCTBs) is a benign but invasive primary bone tumor, accounting for 5% of primary bone tumors . Approximately 50% of giant cell tumors occur around the knee joint . At present, the main surgical treatment options are tumor resection and intralesional curettage .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Giant cell tumors combined with secondary aneurysmal bone cysts are more likely to develop postoperative recurrence: A retrospective study of 256 cases

Tang

Moro

Feng

et al. 2019

Journal of Surgical Oncology

View full text Add to dashboard Cite

Purpose The epidemiology and clinicopathology of aneurysmal bone cysts (ABCs) secondary to giant cell tumors of bone (GCTBs) have been well documented in the previous literature. However, reports on whether secondary ABCs could affect the postoperative recurrence of GCTBs are rare. This study analyzed the effects of secondary ABCs and other relevant clinical factors on the postoperative recurrence of GCTBs of the extremities. Methods We retrospectively analyzed 256 cases of GCTBs of the extremities that were treated surgically at our institution. Among them, there were 60 patients diagnosed with GCTBs combined with secondary ABCs and 196 patients diagnosed with simple GCTBs. Intralesional curettage and tumor resection were performed in 136 and 120 cases, respectively. Univariate analysis, Kaplan‐Meier survival analysis, and multivariate regression analysis were used to assess the factors for postoperative recurrence. The follow‐up period was at least 24 months. Results The total postoperative recurrence rate was 32%. The recurrence rate in the secondary ABCs group was significantly higher than that in the simple GCTBs group (53.3% vs 25.5%, P < 0.05). Curettage was associated with a higher recurrence rate than tumor resection (42.5% vs 20%, P < 0.05). Kaplan‐Meier survival analysis showed that patients with GCTBs combined with secondary ABCs and who were treated by intralesional curettage had a decreased disease‐free survival rate. The hazard ratio was 2.18 (95% confidence interval [CI], 1.15‐4.13) for the group of GCTB combined with ABCs ( P = 0.01) and 1.97 (95% CI, 1.22‐7.50) for the curettage group ( P = 0.01), respectively. Multivariate regression analysis revealed that the presence of secondary ABCs and curettage were independent factors for recurrence of GCTBs. Conclusion According to the results of this study, the presence of secondary ABCs is a potential risk factor for postoperative relapse of GCTBs.

show abstract

“…Although rigorous preoperative design, sophisticated surgical techniques, and standardized postoperative follow-up can maximize the benefit of patients, the risk of recurrence of RGCT remains [35,36]. The therapeutic regimen for recurrence post-operation can be referred to the initial recurrence, which is determined based on the specific conditions of the initial treatment, pathological characteristics, invasive extent, and tumor comorbidity after recurrence.…”

Section: Discussionmentioning

confidence: 99%

Oncology and functional prognosis are both vital in the surgical treatment of RGCTs around the knee joint

Liu

Yuan

et al. 2020

Preprint

View full text Add to dashboard Cite

Aims To explore and provide reasonable surgical options for recurrent giant cell tumors of bone (RGCTs) around the knee joint and compare the pros and cons of extended curettage (EC) and segmental resection (SR). Materials and Methods A retrospective analysis was performed of 22 patients (11 male, 11 female; mean age, 34.1 years) with RGCT around the knee joint treated in our hospital between June 2007 and June 2017. Average recurrence time was 14.2 ± 4.7 months. Basic clinical data, including Campanacci grade, lesion location, filler materials, pathological fracture, were recorded. Based on different reoperation methods, patients were divided into the EC and SR groups. Patients were regularly followed up; and recurrence, metastasis, local complications such as osteoarthritis, infection, prosthesis loosening, were recorded. Patient function and surgical efficacy were evaluated using the musculoskeletal tumor society (MSTS) score and Mankin score, respectively. Results Postoperative recurrence occurred in one patient in both groups, and no difference in the prognosis of oncology was observed between the groups. In the EC group, seven patients developed postoperative complications, but required no surgical treatment, whereas in the SR group, five patients developed postoperative complications and surgical treatment was performed on two patients. There were significant differences in the functional prognosis and surgical efficacy between the two groups; however, the EC group showed more satisfactory results. Conclusion The oncological and functional prognosis of patients with RGCT around the knee joint is vital. EC should be considered as the first-line treatment, unless the tumors severely invade the surrounding soft tissues or are accompanied by complex fractures with significant displacement leading to no surgical curettage boundary.

show abstract

Recurrence Rates and Risk Factors for Primary Giant Cell Tumors around the Knee: A Multicentre Retrospective Study in China

Cited by 41 publications

References 34 publications

Epidemiology of benign giant cell tumor of bone in the Chinese population

Epidemiology of benign giant cell tumor of bone in the Chinese population

Giant cell tumors combined with secondary aneurysmal bone cysts are more likely to develop postoperative recurrence: A retrospective study of 256 cases

Oncology and functional prognosis are both vital in the surgical treatment of RGCTs around the knee joint

Contact Info

Product

Resources

About